Lunai Bioworks (LNAI) FCF Margin (2013 - 2026)

Lunai Bioworks (LNAI) recorded quarterly FCF Margin of 4903.33% in Q1 2026, up 96.14% quarter-over-quarter from 127158.61% in Q2 2016.

Lunai Bioworks (LNAI) FCF Margin (2013 - 2026) Analysis & Trends

Lunai Bioworks' FCF Margin history runs 3 years deep, the most recent figure standing at 4903.33% for Q1 2026.

In Q1 2026, FCF Margin changed N/A year-over-year to 4903.33%; the TTM figure through Mar 2026 stood at 9797.68% (changed N/A YoY), while the FY2016 annual figure was 3442.42%, changed N/A from the prior year.
FCF Margin was 4903.33% for Q1 2026 at Lunai Bioworks, up from 127158.61% in the prior quarter.
In the past five years, FCF Margin ranged from a high of 4903.33% in Q1 2026 to a low of 4903.33% in Q1 2026.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	FCF Margin (Qtr)
1	Alterity Therapeutics	925,601.88 Bn	925,601.85 Bn	-	-
2	Belite Bio	58,560.00 Bn	58,560.00 Bn	-	-
3	Quantum Biopharma	17,284.41 Bn	17,284.40 Bn	-	-
4	Legend Biotech	2,809.00 Bn	2,808.71 Bn	242.10 Mn	-3.98%
5	Evaxion A	1,334.43 Bn	1,334.42 Bn	-	-
6	Akari Therapeutics	1,312.27 Bn	1,312.26 Bn	-	-
7	Psyence Biomedical	212.16 Bn	212.16 Bn	-	-
8	Vertex Pharmaceuticals	114.83 Bn	107.58 Bn	2.59 Bn	43.35%
9	Abivax	91.96 Bn	91.96 Bn	-	-
10	Lunai Bioworks	95.85 Mn	92.70 Mn	20,942.00	-4,903.33%

Download Data